Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Marr

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Leukemia & Lymphoma|October 2, 2012
Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognosticationSarah E Fordham, Helen Marr, James M Allan
Lancet (London, England)|December 17, 2008
Not walking or communicating--is all well?Peter Ganly, Mohamed Saleem, Helen Marr, et al.
International Journal of Molecular Sciences|July 29, 2023
<i>SF3B1</i> Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic LeukemiaErhan Aptullahoglu, Jonathan P Wallis, Helen Marr, et al.
The New Zealand Medical Journal|May 19, 2009
Successful treatment of transplant-associated microangiopathy with rituximabHelen Marr, Emma-Jane McDonald, Eileen Merriman, et al.
Biomedicines|July 27, 2024
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in <i>TP53</i> Wild-Type Chronic Lymphocytic LeukemiaErhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, et al.
Cancers|January 25, 2025
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating <i>TP53</i> Wild-Type Chronic Lymphocytic LeukemiaErhan Aptullahoglu, Mohammed Howladar, Jonathan P Wallis, et al.
International Journal of Molecular Sciences|February 11, 2023
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 InhibitionErhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, et al.
British Journal of Haematology|October 4, 2021
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice PaperToby A Eyre, John C Riches, Piers E M Patten, et al.
Haematologica|April 21, 2019
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cellsCarmela Ciardullo, Erhan Aptullahoglu, Laura Woodhouse, et al.
Annals of Clinical Microbiology and Antimicrobials|December 31, 2021
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapyYusri Taha, Hayley Wardle, Adam B Evans, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|October 2, 2012
Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognosticationSarah E Fordham, Helen Marr, James M Allan
Lancet (London, England)|December 17, 2008
Not walking or communicating--is all well?Peter Ganly, Mohamed Saleem, Helen Marr, et al.
International Journal of Molecular Sciences|July 29, 2023
<i>SF3B1</i> Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic LeukemiaErhan Aptullahoglu, Jonathan P Wallis, Helen Marr, et al.
The New Zealand Medical Journal|May 19, 2009
Successful treatment of transplant-associated microangiopathy with rituximabHelen Marr, Emma-Jane McDonald, Eileen Merriman, et al.
Biomedicines|July 27, 2024
RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in <i>TP53</i> Wild-Type Chronic Lymphocytic LeukemiaErhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, et al.
Cancers|January 25, 2025
Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating <i>TP53</i> Wild-Type Chronic Lymphocytic LeukemiaErhan Aptullahoglu, Mohammed Howladar, Jonathan P Wallis, et al.
International Journal of Molecular Sciences|February 11, 2023
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 InhibitionErhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, et al.
British Journal of Haematology|October 4, 2021
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice PaperToby A Eyre, John C Riches, Piers E M Patten, et al.
Haematologica|April 21, 2019
Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cellsCarmela Ciardullo, Erhan Aptullahoglu, Laura Woodhouse, et al.
Annals of Clinical Microbiology and Antimicrobials|December 31, 2021
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapyYusri Taha, Hayley Wardle, Adam B Evans, et al.
Pageof 2